Cathepsin K Activity Controls Injury-Related Vascular Repair in Mice

Cathepsin K (CatK) is one of the most potent mammalian collagenases. We showed previously the increased expression of CatK in human and animal atherosclerotic lesions. Here, we hypothesized that ablation of CatK mitigates injury-induced neointimal hyperplasia. Male wild-type (CatK+/+) and CatK-deficient (CatK−/−) mice underwent ligation or a combination of ligation and polyethylene cuff-replacement injuries to the right common carotid artery just proximal to its bifurcation, and they were then processed for morphological and biochemical studies at specific time points. On operative day 28, CatK−/− significantly reduced neointimal formation and neovessel formation in both single- and combination-injured arteries compared with the Cat K+/+ mice. At early time points, CatK−/− reduced the lesion macrophage contents and medial smooth muscle cell proliferation, the mRNA levels of monocyte chemoattractant protein-1, toll-like receptor-2, toll-like receptor-4, chemokine ligand-12, and the gelatinolytic activity related to matrix metalloproteinase-2/-9. An aorta-explant assay revealed that smooth muscle cell movement was impaired in the CatK−/− mice compared with the CatK+/+ mice. In addition, the smooth muscle cells and macrophages from CatK−/− mice had less invasive ability through a reconstituted basement membrane barrier. This vasculoprotective effect was mimicked by Cat inhibition with trans-epoxysuccinyl-L-leucylamido-{4-guanidino} butane (E64d). These results demonstrate an essential role of CatK in neointimal lesion formation in response to injury, possibly via the reduction of toll-like receptor-2/-4–mediated inflammation and smooth muscle cell proliferation, suggesting a novel therapeutic strategy for the control of endovascular treatment–related restenosis by regulating CatK activity.

[1]  P. Libby,et al.  Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. , 2013, Cardiovascular research.

[2]  P. Libby.  Mechanisms of acute coronary syndromes and their implications for therapy. , 2013, The New England journal of medicine.

[3]  K. Okumura,et al.  Circulating cathepsin K as a potential novel biomarker of coronary artery disease. , 2013, Atherosclerosis.

[4]  K. Okumura,et al.  Role for Cysteine Protease Cathepsins in Heart Disease: Focus on Biology and Mechanisms With Clinical Implication , 2012, Circulation.

[5]  X. Cheng,et al.  Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. , 2012, Arthritis and rheumatism.

[6]  N. Dhalla,et al.  Role of various proteases in cardiac remodeling and progression of heart failure , 2012, Heart Failure Reviews.

[7]  K. Okumura,et al.  Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.

[8]  P. Libby,et al.  Cathepsin L Activity Is Essential to Elastase Perfusion–Induced Abdominal Aortic Aneurysms in Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[9]  H. Björkbacka,et al.  The vascular repair process after injury of the carotid artery is regulated by IL-1RI and MyD88 signalling. , 2011, Cardiovascular Research.

[10]  K. Okumura,et al.  Angiotensin Type 1 Receptor Blocker Reduces Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice , 2011, Hypertension.

[11]  B. Wang,et al.  Cystatin C Deficiency Promotes Epidermal Dysplasia in K14-HPV16 Transgenic Mice , 2010, PloS one.

[12]  K. Okumura,et al.  AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. , 2010, Atherosclerosis.

[13]  S. Abraham,et al.  Salmonella disrupts lymph node architecture by TLR4-mediated suppression of homeostatic chemokines , 2009, Nature Medicine.

[14]  T. V. van Berkel,et al.  Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. , 2008, Cardiovascular research.

[15]  R. Maser,et al.  Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1. , 2008, American journal of physiology. Renal physiology.

[16]  J. Kos,et al.  Cysteine protease cathepsin X modulates immune response via activation of β2 integrins , 2008, Immunology.

[17]  T. Hawn,et al.  Toll-Like Receptor-4 Mediates Vascular Inflammation and Insulin Resistance in Diet-Induced Obesity , 2007, Circulation research.

[18]  K. Okumura,et al.  Mechanisms Underlying the Impairment of Ischemia-Induced Neovascularization in Matrix Metalloproteinase 2–Deficient Mice , 2007, Circulation research.

[19]  H. Izawa,et al.  Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure , 2006, Hypertension.

[20]  Tomoaki Koga,et al.  The Transforming Growth Factor-β-Smad3/4 Signaling Pathway Acts as a Positive Regulator for TLR2 Induction by Bacteria via a Dual Mechanism Involving Functional Cooperation with NF-κB and MAPK Phosphatase 1-dependent Negative Cross-talk with p38 MAPK* , 2006, Journal of Biological Chemistry.

[21]  P. Kitslaar,et al.  Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. , 2006, Microbes and infection.

[22]  X. Cheng,et al.  A Simple Method of Plaque Rupture Induction in Apolipoprotein E–Deficient Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  T. Murohara,et al.  Localization of Cysteine Protease, Cathepsin S, to the Surface of Vascular Smooth Muscle Cells by Association with Integrin ανβ3 , 2006 .

[24]  I. van der Made,et al.  Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation , 2005, Circulation.

[25]  T. Murohara,et al.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. , 2006, The American journal of pathology.

[26]  S. Wahl,et al.  Aberrant Toll Receptor Expression and Endotoxin Hypersensitivity in Mice Lacking a Functional TGF-β1 Signaling Pathway , 2004, The Journal of Immunology.

[27]  X. Cheng,et al.  Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. , 2004, The American journal of pathology.

[28]  S. Itohara,et al.  Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia , 2003, Circulation.

[29]  David Zurakowski,et al.  Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Libby,et al.  Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth , 2003, Circulation research.

[31]  G. Hansson,et al.  Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation , 2002, Circulation.

[32]  D. Golenbock,et al.  Chlamydia pneumoniae and Chlamydial Heat Shock Protein 60 Stimulate Proliferation of Human Vascular Smooth Muscle Cells via Toll-Like Receptor 4 and p44/p42 Mitogen-Activated Protein Kinase Activation , 2001, Circulation research.

[33]  D. Brömme,et al.  Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. , 2000, Biochemistry.

[34]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[35]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.